Cervical Cancer FIGO Stage IA2, IB, or IIA: Adjuvant Treatment Following Hysterectomy
Clinical Scenario
This protocol addresses patients with cervical cancer classified as FIGO stage IA2, stage IB, or stage IIA. In this population, radical hysterectomy with bilateral lymph node dissection is the established surgical approach for patients who do not wish to preserve fertility.
Post-Surgical Management
After hysterectomy, risk stratification determines whether adjuvant therapy is indicated. High-risk patients are candidates for adjuvant chemoradiotherapy (CRT); the regimen involves a chemotherapy backbone combined with radiotherapy, administered over multiple courses. The complete protocol — including eligibility criteria, sequencing, and course details — is available in the full structured regimen.
Full regimen details, dosing, and course schedule are in the structured protocol.
Approach
Adjuvant chemoradiotherapy is recommended for high-risk patients in this staging group following hysterectomy. The treatment involves a radiotherapy-chemotherapy combination; intermediate-risk patients may not require further adjuvant intervention. The complete evidence-based regimen is structured behind the access link.
References
DOI: 10.1093/annonc/mdx220
In patients with FIGO stage IA2, IB and IIA, radical hysterectomy with bilateral lymph node dissection (with or without SLN) is standard treatment, if the patient does not wish to preserve fertility [I, B].
In this setting of patients, adjuvant CRT is indicated based on a clinical trial that randomly assigned 268 women IA2, IB and IIA to adjuvant RT with or without chemotherapy (cisplatin–5-fluorouracil) for four courses.
Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is recommended in high-risk patients [I, A].
View source ↗